Skip to main content
. 2012 Nov 9;5(1):64–79. doi: 10.1002/emmm.201201544

Figure 3. Leukocyte FoxP3 and CD25 mRNA expression levels are reduced in rapidly progressing ALS patients.

Figure 3

qRT-PCR was utilized to evaluate mRNA expression levels of FoxP3 and CD25 in leukocytes obtained from 54 ALS patients through all stages of disease and 33 control volunteers.

  • A,B. FoxP3 mRNA expression levels were down-regulated in rapidly progressing ALS patients (t-test) and negatively correlated with disease progression rates (R = 0.419; linear regression).
  • C,D. CD25 mRNA expression levels were reduced in rapidly progressing ALS patients (t-test) and inversely correlated with rate of disease progression (R = 0.444; linear regression).
  • E. FoxP3 and CD25 mRNA expression levels of ALS patients directly correlated with each other (R = 0.815; linear regression). Note that slowly progressing patients early in their disease expressed the highest FoxP3 and CD25 mRNA levels, whereas rapidly progressing patients late in their course of disease expressed the lowest levels of FoxP3 and CD25 mRNAs. ##p ≤ 0.005 versus slowly progressing ALS patients. ***p ≤ 0.001 versus controls. &&p ≤ 0.005, &&&p ≤ 0.001.